A phase 3 clinical trial of veligrotug, an anti-insulin-like growth factor-1 receptor antibody, met primary and secondary endpoints involving proptosis, clinical activity scores and diplopia for the treatment of chronic thyroid eye disease.
According to a press release from Viridian Therapeutics, 188 patients with chronic thyroid eye disease were randomly assigned to receive veligrotug (125 patients) or placebo (63 patients) in the THRIVE-2 trial. Participants received five infusions of veligrotug, and endpoints were assessed at 15 weeks.
The proptosis responder rate, defined as at least a 2 mm